NCT00407563 - Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Epithelial Ovarian CancerPrimary Peritoneal Carcinoma

Interventions

DRUG

Bevacizumab

Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.

DRUG

Abraxane

Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.

Trial Locations (11)

Pennsylvania Oncology Hematology Assoc., Philadelphia

Cancer Specialists of Tidewater, Ltd, Chesapeake

Southeastern Gynecologic Oncology, LLC, Atlanta

Northeast Georgia Cancer Care, LLC, Athens

Chattanooga's Program in Women's Oncology, Chattanooga

The West Clinic, Memphis

North Idaho Cancer Center, Coeur d'Alene

Mid-Ohio Oncology/Hematology, Columbus

Hematology-Oncology Centers of the Northern Rockies, Billings

Little Rock Hematology Oncology, Little Rock

Wilshire Oncology Medical Group, Inc., La Verne